SRTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Sensus Healthcare Inc (SRTS) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The company's financial performance has been significantly weak, with revenue, net income, and EPS showing substantial declines. Additionally, there are no strong positive catalysts or recent trading signals to support an immediate buy decision. It is advisable to monitor the stock for potential improvements in financials or market sentiment before considering an investment.
The technical indicators suggest a neutral to slightly bearish trend. The MACD is below 0 and negatively contracting, the RSI is neutral at 41.611, and moving averages are converging. The stock is trading below the pivot level of 4.17, with key support at 3.621 and resistance at 4.719.
NULL identified. No recent news or significant trading activity from insiders, hedge funds, or influential figures.
Weak Q4 financial performance with revenue down 62.20% YoY, net income down 304.85% YoY, and EPS down 311.11% YoY. Gross margin also dropped significantly. Analysts have lowered the price target from $8 to $6, citing poor results.
In Q4 2025, revenue dropped to $4.939 million (-62.20% YoY), net income dropped to -$3.167 million (-304.85% YoY), and EPS dropped to -0.19 (-311.11% YoY). Gross margin declined to 38.43% (-29.34% YoY).
Maxim analyst Anthony Vendetti lowered the price target from $8 to $6 while maintaining a Buy rating. The downgrade was due to significantly below-expectation Q4 results, primarily attributed to no sales from the company's largest customer.
